Core C: Experimental Models
Core C: Experimental Models
批准号:
10263186
负责人:
MICHAEL E. BERENS
金额:
$25.11万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-14 至 2026-06-30
关键词:
Animal ModelAstrocytesBehaviorBloodBrain NeoplasmsCellsCellular Indexing of Transcriptomes and Epitopes by SequencingCharacteristicsClinicClinical DataCollectionDNADataDatabasesDominant-Negative MutationElectroporationEngineeringEventExperimental ModelsFTH1 geneFemaleFour Core GenotypesFreezingGenerationsGenesGeneticGenetically Engineered MouseGenomicsGlioblastomaGliomaGoalsGonadal Steroid HormonesGrowthGuidelinesH ferritinHeterogeneityHumanIACUCImplantIndividualInformaticsInfrastructureInstitutionInstitutional Review BoardsIronKaryotype determination procedureKnock-outKnockout MiceLCN2 geneLabelModelingMusNeurofibromatosis 1OrganoidsOutcomeParaffinPathologyPatientsPerformancePloidiesPopulationPre-Clinical ModelPreclinical TestingQuality ControlReporterResearch PersonnelResourcesSecureServicesSex ChromosomesSex DifferencesSpecimenStandardizationTP53 geneTechnologyTestingTestisTissue BanksTissuesTreatment outcomeTumor Cell LineUniversitiesUniversity HospitalsValidationXenograft procedureY Chromosomeautosomebasebiobankcancer imagingcell transformationclinically relevantcost effectivedata sharingexperimental studyhuman subjecthuman tissueimaging platformin uteroin vivoin vivo imagingin vivo two-photon imaginginnovationjunctional adhesion moleculemalemodel developmentmouse modelneoplastic cellpathology imagingpatient derived xenograft modelquality assuranceradiological imagingresponsesexsry Genestranscriptome sequencingtranscriptomicstumor microenvironmenttwo photon microscopy
中文摘要
项目总结
实验模型核心负责管理、跟踪、质量控制和分发所有
胶质母细胞瘤(GBM)动物模型(患者来源的异种移植(PDX)模型,PDX来源的有机化合物,同基因
小鼠和基因工程小鼠),用于所有项目的实验研究和来自人类的生物标本
用于跨多个机构进行验证。核心还将负责从
这些模型,对于小鼠肿瘤的双光子体内成像,以及对于单细胞和空间转录
P01的技术资源。一套>;180 PDX GBM模型和>;5同基因小鼠模型
基因组图谱(DNA、RNA测序)可用于项目的假设检验。人体标本
证实小鼠模型的发现将有助于验证性别差异,尽管
将人类患者与老鼠模型进行比较是一个警告。核心加强项目和P01通过
协调用于实验研究的模型的分布,其中肿瘤细胞的性别是
通过性基因特异性聚合酶链式反应和性染色体核型鉴定。试验性项目的目标
模型核心将通过以下具体目标来实现:1)创建、组织和维护
基础设施,然后部署同基因和基因工程小鼠胶质瘤模型,患者来源
异种GBM模型、短期GBM培养和有机物,提供高质量、科学相关的
使用标准化的收集、质量控制、储存/跟踪和分发向P01调查人员提供生物检疫
根据批准的IACUC指南,以及2)制造高质量的、具有科学相关性的临床生物检验品
通过不断努力和创新,向P01调查人员提供标准化收集、质量
控制(包括集中的神经病理检查)、存储/跟踪和在适当的人类环境下分发
使用安全、易于访问的数据库的主题(OHRP)监管指南。一个明确的好处是
实验模型核心是跨所有项目共享使用模型的协调和可见性,
共享质量控制、批次(或通过)效应、生长特性、基因组图谱和跨项目
共享实验结果的数据。
英文摘要
PROJECT SUMMARY
The Experimental Models Core is responsible for curation, tracking, quality control, and distribution of all
glioblastoma (GBM) animal models (patient-derived xenograft (PDX) models, PDX-derived organoids, syngeneic
mouse and genetically engineered mice) for experimental studies in all Projects and biospecimens from humans
for validation across multiple institutions. The Core will also be responsible for the generation of organoids from
these models, for two-photon in vivo imaging of tumors in mice, and for single cell and spatial transcriptomics as
technology resources for the P01. A suite of >180 PDX GBM models and >5 syngeneic mouse models with
genomic profiling (DNA, RNA sequencing) are available for hypothesis testing by the projects. Human specimens
to confirm findings from mouse models will help validate sex differences, albeit the innate heterogeneity across
human patients compared to mouse models is a caveat. The core strengthens the projects and the P01 by
coordinating the distribution of models for experimental studies in which the sex of the tumor cells are
characterized via sex gene-specific PCR and sex chromosome karyotyping. The goals of the Experimental
Models Core will be accomplished through the following specific aims: 1) To create, organize, and maintain
infrastructure, then deploy syngeneic and genetically engineered mouse glioma models, patient-derived
xenograft GBM models, short-term GBM cultures and organoids, providing high-quality, scientifically relevant
biospecimens to P01 investigators using standardized collection, quality control, storage/tracking and distribution
under approved IACUC guidelines, and 2) To make high-quality, scientifically-relevant clinical biospecimens
available to the P01 investigators through continued efforts and innovations in standardized collection, quality
control (including centralized neuro pathology review), storage/tracking and distribution under proper human
subject (OHRP) regulatory guidelines using secure, readily accessible databases. A decided benefit of the
Experimental Models Core is the coordination and visibility of shared use of models across all Projects, with
shared quality control, batch (or passage) effects, growth characteristics, genomic profiling, and cross-Project
data sharing from the experimental outcomes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Signature-guided treatment of GBM with neddylation inhibitor pevonedistat
-
批准号:10488225
-
项目类别:
-
资助金额:$20.06万
-
财政年份:2021
-
负责人:MICHAEL E. BERENS
-
依托单位:
Signature-guided treatment of GBM with neddylation inhibitor pevonedistat
-
批准号:10696195
-
项目类别:
-
资助金额:$19.62万
-
财政年份:2021
-
负责人:MICHAEL E. BERENS
-
依托单位:
Molecular Profiling and Bioinformatics
-
批准号:10306303
-
项目类别:
-
资助金额:$13.09万
-
财政年份:2021
-
负责人:MICHAEL E. BERENS
-
依托单位:
Molecular Profiling and Bioinformatics
-
批准号:10488209
-
项目类别:
-
资助金额:$13.11万
-
财政年份:2021
-
负责人:MICHAEL E. BERENS
-
依托单位:
Molecular Profiling and Bioinformatics
-
批准号:10696184
-
项目类别:
-
资助金额:$17.52万
-
财政年份:2021
-
负责人:MICHAEL E. BERENS
-
依托单位:
Signature-guided treatment of GBM with neddylation inhibitor pevonedistat
-
批准号:10306306
-
项目类别:
-
资助金额:$23.47万
-
财政年份:2021
-
负责人:MICHAEL E. BERENS
-
依托单位:
Core C: Experimental Models
-
批准号:10463734
-
项目类别:
-
资助金额:$54.89万
-
财政年份:2020
-
负责人:MICHAEL E. BERENS
-
依托单位:
Core C: Experimental Models
-
批准号:10023719
-
项目类别:
-
资助金额:$58.95万
-
财政年份:2020
-
负责人:MICHAEL E. BERENS
-
依托单位:
Core C: Experimental Models
-
批准号:10653109
-
项目类别:
-
资助金额:$54.82万
-
财政年份:2020
-
负责人:MICHAEL E. BERENS
-
依托单位:
Credentialing murine models for glioblastoma preclinical drug development
-
批准号:9986359
-
项目类别:
-
资助金额:$47.23万
-
财政年份:2016
-
负责人:MICHAEL E. BERENS
-
依托单位:
Systematic Development of Novel, Druggable Cancer Targets
-
批准号:8323848
-
项目类别:
-
资助金额:$88.71万
-
财政年份:2012
-
负责人:MICHAEL E. BERENS
-
依托单位:
Systematic Development of Novel, Druggable Cancer Targets
-
批准号:8464685
-
项目类别:
-
资助金额:$78.3万
-
财政年份:2012
-
负责人:MICHAEL E. BERENS
-
依托单位:
Systematic Development of Novel, Druggable Cancer Targets
-
批准号:8663201
-
项目类别:
-
资助金额:$78.85万
-
财政年份:2012
-
负责人:MICHAEL E. BERENS
-
依托单位:
Systematic Development of Novel, Druggable Cancer Targets
-
批准号:8850252
-
项目类别:
-
资助金额:$80.56万
-
财政年份:2012
-
负责人:MICHAEL E. BERENS
-
依托单位:
Systematic Development of Novel, Druggable Cancer Targets
-
批准号:9057986
-
项目类别:
-
资助金额:$79.42万
-
财政年份:2012
-
负责人:MICHAEL E. BERENS
-
依托单位:
The Southwest Comprehensive Center for Drug Discovery and Development
-
批准号:7942802
-
项目类别:
-
资助金额:$270.05万
-
财政年份:2009
-
负责人:MICHAEL E. BERENS
-
依托单位:
Arrested migration fosters apoptosis of glioma cells
-
批准号:6805713
-
项目类别:
-
资助金额:$21.97万
-
财政年份:2003
-
负责人:MICHAEL E. BERENS
-
依托单位:
Arrested migration fosters apoptosis of glioma cells
-
批准号:6582331
-
项目类别:
-
资助金额:$19.31万
-
财政年份:2003
-
负责人:MICHAEL E. BERENS
-
依托单位:
Genetic Pathways of Glioma Invasion
-
批准号:6530031
-
项目类别:
-
资助金额:$44.77万
-
财政年份:2001
-
负责人:MICHAEL E. BERENS
-
依托单位:
Genetic Pathways of Glioma Invasion
-
批准号:6653804
-
项目类别:
-
资助金额:$49.99万
-
财政年份:2001
-
负责人:MICHAEL E. BERENS
-
依托单位:
国内基金
海外基金
Ascl1介导Wnt/beta-catenin通路在TLE海马硬化中反应性Astrocytes异常增生的作用及调控机制
-
批准号:31760279
-
项目类别:地区科学基金项目
-
资助金额:35.0万元
-
批准年份:2017
-
负责人:丁银秀
-
依托单位: